Table 2 The change in best-corrected visual acuity (BCVA), central retinal thickness, subfoveal choroidal thickness and choroidal vascularity index from baseline to month 3, 6 and 12 for eyes with typical AMD or PCV completing 12-month study.

Best-corrected visual acuity, LogMAR

0.833, 0.542

0.690, 0.501

<0.01

0.666, 0.533

0.022

0.548, 0.512

0.025

Central retinal thickness, µm

438.3, 122.9

345.3, 131.7

<0.001

370.8, 126.5

0.0072

353.3, 136.7

<0.001

Subfoveal choroidal thickness, µm

226.7, 92.1

198.1, 81.4

<0.001

189.8, 85.1

<0.001

184.0, 48.1

<0.001

Choroidal vascular index (CVI), %

62.3, 2.8

63.5, 3.3

0.316

63.4, 3.5

0.222

63.5, 3.5

0.391

Total choroidal area (TCA)

3.63, 1.09

2.81, 0.88

<0.001

2.84,0.86

<0.001

2.86, 0.88

<0.001

Luminal area (LA)

2.24, 0.67

1.76, 0.58

<0.001

1.80, 0.57

<0.001

1.78, 0.56

<0.001

Stromal Area (SA)

1.40, 0.44

1.05, 0.32

<0.001

1.04, 0.31

<0.001

1.09, 0.35

<0.001

Anti-VEGF injections (mean cumulative)

2.24, 1.10

3.11, 1.00

4.28, 1.48

Best-corrected visual acuity, LogMAR

0.78, 0.54

0.674, 0.586

0.422

0.683, 0.581

0.283

0.614, 0.542

0.125

Central retinal thickness, µm

472.1, 219.8

307.8, 121.4

<0.001

304.8, 110.6

<0.001

317.4, 115.7

<0.001

Subfoveal choroidal thickness, µm

237.6, 85.6

212.5, 84.0

<0.01

208.4, 91.8

<0.001

189.0, 48.5

<0.001

Choroidal vascular index (CVI), %

61.9, 3.1

63.2, 3.1

0.100

63.0, 3.5

0.213

62.5, 3.7

0.350

Total choroidal area (TCA)

3.71, 1.16

3.14, 1.07

<0.001

2.95, 1.00

<0.001

2.99, 0.99

<0.001

Luminal area (LA)

2.29, 0.70

1.99, 0.72

<0.001

1.87, 0.66

<0.001

1.87, 0.68

<0.001

Stromal Area (SA)

1.42, 0.48

1.15, 0.37

<0.001

1.08, 0.36

<0.001

1.12, 0.33

<0.001

Anti-VEGF injections (mean cumulative)

2.36, 0.87

3.34, 1.13

3.92, 1.08

PDT injections (mean cumulative)

0.37, 0.53

0.46, 0.62

0.49, 0.67